Effect of Nicorandil Treatment Adjunctive to Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: a Systematic Review and Meta-analysis

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2020 Nov 30

PMID 33249959

Citations 5

Authors

Jin Zhou

Jing Xu

Aijuan Cheng

Peng Li

Bingwei Chen

Shan Sun

Affiliations

Soon will be listed here.

Abstract

Objective: There is controversy whether nicorandil treatment has cardioprotective effects in patients with acute myocardial infarction (AMI) following percutaneous coronary intervention (PCI). This meta-analysis was conducted to assess the efficacy of nicorandil on functional and clinical outcomes after PCI.

Methods: Systematic databases were searched to retrieve studies that compared the effect of nicorandil with a control group in patients with AMI who underwent PCI. Outcomes related to coronary blood flow, and functional and clinical outcomes were extracted and a meta-analysis was performed. Trial sequential analysis was conducted to estimate the required sample size for statistical power.

Results: Twenty-four trials involving 2965 patients with AMI were enrolled. Pooled results showed that nicorandil treatment significantly suppressed the incidence of no-reflow phenomenon and reperfusion arrhythmia after reperfusion, improved the left ventricular ejection fraction and left ventricular end-systolic volume index, and reduced major adverse cardiovascular events and cardiovascular death. Trial sequential analysis confirmed the effect of nicorandil in reducing the incidence of no-reflow phenomenon and follow-up major adverse cardiovascular events in patients with AMI after PCI.

Conclusion: Our findings suggest that nicorandil treatment adjunctive to reperfusion therapy improves myocardial reperfusion, cardiac function, and clinical outcomes in patients with AMI.

Citing Articles

Nicorandil as a promising therapeutic option for ventricular arrhythmia: A case report and review of literature.

Bai L, Zhao M, Ma K World J Cardiol. 2024; 16(12):768-775.

PMID: 39734814 PMC: 11669980. DOI: 10.4330/wjc.v16.i12.768.

Mechanism of Coronary Microcirculation Obstruction after Acute Myocardial Infarction and Cardioprotective Strategies.

Li Y, Yu J, Wang Y Rev Cardiovasc Med. 2024; 25(10):367.

PMID: 39484142 PMC: 11522835. DOI: 10.31083/j.rcm2510367.

Chinese expert consensus on the diagnosis and treatment of coronary microvascular diseases (2023 Edition).

Chen W, Ni M, Huang H, Cong H, Fu X, Gao W MedComm (2020). 2023; 4(6):e438.

PMID: 38116064 PMC: 10729292. DOI: 10.1002/mco2.438.

Nicorandil, Novel Potassium Adenosine Triphosphate Channel (K+ ATP) Opener in Ischemia With Non-Obstructive Coronary Arteries (INOCA) and Atherosclerotic Cardiovascular Disease (ASCVD): Delphi Consensus Statement.

Chakraborty R Cureus. 2023; 15(1):e33624.

PMID: 36643082 PMC: 9835851. DOI: 10.7759/cureus.33624.

Assessment of the Efficacy and Safety of Early Intracoronary Nicorandil Administration in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Gupta H, Parihar S, Tripathi V Cureus. 2022; 14(5):e25349.

PMID: 35761910 PMC: 9233414. DOI: 10.7759/cureus.25349.

References

Ono H, Osanai T, Ishizaka H, Hanada H, Kamada T, Onodera H . Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J. 2004; 148(4):E15. DOI: 10.1016/j.ahj.2004.05.014. View

Niu X, Zhang J, Bai M, Peng Y, Sun S, Zhang Z . Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis. BMC Cardiovasc Disord. 2018; 18(1):3. PMC: 5763527. DOI: 10.1186/s12872-017-0722-z. View

Hwang J, Lee H, Kim B, Yang M, Park J, Park J . Effect on periprocedural myocardial infarction of intra-coronary nicorandil prior to percutaneous coronary intervention in stable and unstable angina. J Cardiol. 2013; 62(2):77-81. DOI: 10.1016/j.jjcc.2013.03.017. View

Reffelmann T, Kloner R . The "no-reflow" phenomenon: basic science and clinical correlates. Heart. 2002; 87(2):162-8. PMC: 1767011. DOI: 10.1136/heart.87.2.162. View

Shi L, Chen L, Qi G, Tian W, Zhao S . Effects of Intracoronary Nicorandil on Myocardial Microcirculation and Clinical Outcomes in Patients with Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials. Am J Cardiovasc Drugs. 2019; 20(2):191-198. DOI: 10.1007/s40256-019-00368-y. View

Kobayashi Y, Goto Y, Daikoku S, Itoh A, Miyazaki S, Ohshima S . Cardioprotective effect of intravenous nicorandil in patients with successful reperfusion for acute myocardial infarction. Jpn Circ J. 1998; 62(3):183-9. DOI: 10.1253/jcj.62.183. View

Kloner R . Does reperfusion injury exist in humans?. J Am Coll Cardiol. 1993; 21(2):537-45. DOI: 10.1016/0735-1097(93)90700-b. View

Qi Q, Niu J, Chen T, Yin H, Wang T, Jiang Z . Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction. Med Sci Monit. 2018; 24:2767-2776. PMC: 5954842. DOI: 10.12659/MSM.906815. View

Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T . Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol. 1999; 33(3):654-60. DOI: 10.1016/s0735-1097(98)00604-4. View

10.

Li J, Xu X, Zhou X, Dai J, Ma L, Chen C . Cardiovascular events associated with nicorandil administration prior to primary percutaneous coronary intervention in patients with acute ST-segment elevated myocardial infarction: a systematic review and meta-analysis. Expert Opin Drug Saf. 2019; 18(6):537-547. DOI: 10.1080/14740338.2019.1617848. View

11.

Gibson C, Cannon C, Murphy S, Ryan K, Mesley R, MARBLE S . Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000; 101(2):125-30. DOI: 10.1161/01.cir.101.2.125. View

12.

Thorlund K, Devereaux P, Wetterslev J, Guyatt G, Ioannidis J, Thabane L . Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. Int J Epidemiol. 2008; 38(1):276-86. DOI: 10.1093/ije/dyn179. View

13.

Nameki M, Ishibashi I, Miyazaki Y, Sakai Y, Namikawa S, Kuriyama N . Comparison between nicorandil and magnesium as an adjunct cardioprotective agent to percutaneous coronary intervention in acute anterior myocardial infarction. Circ J. 2004; 68(3):192-7. DOI: 10.1253/circj.68.192. View

14.

Kim S, Kim W, Woo J, Ha S, Kang W, Hwang S . Effect of myocardial protection of intracoronary adenosine and nicorandil injection in patients undergoing non-urgent percutaneous coronary intervention: a randomized controlled trial. Int J Cardiol. 2011; 158(1):88-92. DOI: 10.1016/j.ijcard.2011.01.011. View

15.

Liang T, Liu M, Wu C, Zhang Q, Lu L, Wang Z . Risk Factors for No-Reflow Phenomenon after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome. Rev Invest Clin. 2017; 69(3):139-145. DOI: 10.24875/ric.17002190. View

16.

Ji Z, Zhang R, Lu W, Ma G, Qu Y . The effect of nicorandil in patients with acute myocardial infarction undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Ir J Med Sci. 2019; 189(1):119-131. DOI: 10.1007/s11845-019-02034-3. View

17.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

18.

J E, Juneja M, George T, Sr R, V V, Ak B . Prevention of no flow/slow reflow phenomenon in primary PCI by Nicorandil. Indian Heart J. 2009; 59(3):246-9. View

19.

Suematsu Y, Murasato Y, Miura S, Horiuchi M, Yamamoto T, Takata K . Safety and feasibility of high-dose administration of nicorandil before reperfusion therapy in acute myocardial infarction. Cardiovasc Interv Ther. 2013; 28(4):352-61. DOI: 10.1007/s12928-013-0182-z. View

20.

Lee H, An S, Choi J, Lee T, Kim J, Kim J . Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction. Circ J. 2008; 72(9):1425-9. DOI: 10.1253/circj.cj-08-0212. View